Semaglutide (Ozempic/Wegovy): The Complete Guide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has reshaped the landscape of obesity medicine and type 2 diabetes management. Originally developed by Novo Nordisk, semaglutide mimics a naturally occurring gut hormone that regulates appetite, blood sugar, and digestion. It is currently available under three brand names:
- Ozempic — injectable semaglutide 0.5 mg, 1 mg, or 2 mg once weekly (approved for type 2 diabetes)
- Wegovy — injectable semaglutide 2.4 mg once weekly (approved for chronic weight management)
- Rybelsus — oral semaglutide tablet 7 mg or 14 mg once daily (approved for type 2 diabetes)
Few medications in recent history have generated as much scientific interest — or popular attention — as semaglutide. Its approval for weight loss in 2021 marked the first time a medication had demonstrated double-digit average weight reductions in clinical trials, validating obesity as a metabolic disease rather than a character failing.
How Semaglutide Works: Mechanism of Action
Semaglutide is a synthetic analog of the endogenous GLP-1 hormone, engineered with a half-life of approximately one week (compared to minutes for the natural hormone). It exerts its effects through several complementary pathways:
1. Appetite Suppression
GLP-1 receptors are densely expressed in the hypothalamus and brainstem — the brain's hunger and satiety control centers. Semaglutide activates these receptors, reducing appetite and food cravings, and increasing feelings of fullness after meals. This central action is the primary driver of weight loss.
2. Gastric Emptying
Semaglutide slows the rate at which food moves from the stomach into the small intestine. This delays nutrient absorption, prolongs satiety after eating, and blunts postprandial blood sugar spikes.
3. Insulin Secretion and Glucagon Suppression
In the pancreas, semaglutide stimulates glucose-dependent insulin release and suppresses glucagon secretion. Critically, this only occurs when blood sugar is elevated — dramatically reducing the risk of hypoglycemia compared to older diabetes drugs.
4. Cardiovascular and Organ Effects
Beyond glucose and weight, GLP-1 receptors are found in the heart, kidneys, and liver. Semaglutide has demonstrated meaningful reductions in cardiovascular events, kidney disease progression, and liver fat — benefits that extend well beyond its metabolic effects.
FDA Approvals and Indications
| Indication | Brand | Status |
|---|---|---|
| Type 2 diabetes (injectable) | Ozempic | FDA-approved (2017) |
| Chronic weight management | Wegovy | FDA-approved (2021) |
| Type 2 diabetes (oral) | Rybelsus | FDA-approved (2019) |
| Cardiovascular risk reduction | Ozempic / Wegovy | FDA-approved (2023–2024) |
| Chronic kidney disease (CKD) reduction | Ozempic | FDA-approved (2024) |
| Obstructive sleep apnea | Wegovy | FDA-approved (2024) |
The cardiovascular indication was granted after the landmark SELECT trial demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE) in people with obesity who did not have diabetes.
Dosing Protocols
Ozempic (Type 2 Diabetes — Subcutaneous Injection)
Ozempic follows a structured dose escalation designed to minimize gastrointestinal side effects:
| Weeks | Dose |
|---|---|
| 1–4 | 0.25 mg once weekly (starter dose) |
| 5–8 | 0.5 mg once weekly |
| 9+ | 1 mg once weekly (maintenance) |
| Optional | 2 mg once weekly (if additional glycemic control needed) |
Wegovy (Weight Management — Subcutaneous Injection)
Wegovy uses a slower escalation to reach a higher maintenance dose:
| Weeks | Dose |
|---|---|
| 1–4 | 0.25 mg once weekly |
| 5–8 | 0.5 mg once weekly |
| 9–12 | 1 mg once weekly |
| 13–16 | 1.7 mg once weekly |
| 17+ | 2.4 mg once weekly (maintenance) |
Both are self-administered as a subcutaneous injection into the abdomen, thigh, or upper arm. The subcutaneous route offers approximately 89% bioavailability, with peak serum concentrations reached within 1–3 days and steady-state achieved after 4–5 weeks.
Rybelsus (Oral — Type 2 Diabetes)
- Weeks 1–30: 3 mg once daily (tolerability — not therapeutically effective)
- Weeks 31+: 7 mg once daily
- If needed: 14 mg once daily
Rybelsus must be taken on an empty stomach with no more than 4 oz of water, at least 30 minutes before eating or drinking anything else.
Clinical Trial Results: What the Data Shows
STEP 1 Trial (Wegovy 2.4 mg)
The pivotal STEP 1 trial enrolled 1,961 adults with obesity and followed them for 68 weeks:
- Average weight loss: −14.9% with semaglutide vs. −2.4% with placebo
- ≥5% weight loss: 86% of semaglutide participants vs. 32% with placebo
- ≥10% weight loss: 70% of semaglutide participants vs. 12% with placebo
- ≥15% weight loss: 50% of semaglutide participants vs. 5% with placebo
STEP 5 Trial (Long-Term, 2 Years)
The STEP 5 trial extended follow-up to 104 weeks, demonstrating sustained weight loss of −15.2% body weight at 2 years. Discontinuation resulted in weight regain, underscoring that semaglutide treats a chronic condition.
SELECT Trial (Cardiovascular Outcomes)
The SELECT trial enrolled 17,604 adults with obesity and established cardiovascular disease but without diabetes:
- MACE reduction: 6.5% vs. 8.0% — a 20% relative risk reduction in heart attack, stroke, or cardiovascular death
- This was the first weight-loss medication to demonstrate cardiovascular benefit in a large outcomes trial
Long-Term 4-Year Data
At 208 weeks, semaglutide was associated with −10.2% mean body weight reduction vs. −1.5% with placebo, with sustained cardiometabolic improvements in blood pressure, cholesterol, and glycemic markers.
Higher Dose Investigations (2025)
Emerging 2025 data showed that a 7.2 mg dose of semaglutide led to average weight loss of approximately 19%, with nearly half of participants losing 20% or more of their body weight — approaching results seen with bariatric surgery.
Side Effects
Common Side Effects
Gastrointestinal symptoms are the most frequent complaint, especially during dose escalation:
- Nausea (most common, affects ~44% of Wegovy users)
- Vomiting, diarrhea, constipation
- Abdominal discomfort or bloating
- Belching / heartburn
- Fatigue, headache, dizziness
These symptoms are typically worst during dose increases and improve over time.
Serious but Rare Side Effects
- Acute pancreatitis — discontinue if severe abdominal pain occurs
- Gallbladder disease — rapid weight loss increases gallstone risk
- Acute kidney injury — often secondary to dehydration from GI side effects
- Diabetic retinopathy worsening — monitor closely in patients with pre-existing retinopathy
- Thyroid C-cell tumors — observed in rodent studies; contraindicated in personal/family history of medullary thyroid carcinoma (MTC) or MEN2
Anesthesia Considerations
Due to delayed gastric emptying, many anesthesiologists recommend holding semaglutide for at least one dosing cycle before elective procedures requiring general anesthesia.
Semaglutide vs. Tirzepatide: Key Differences
| Feature | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Max approved dose | 2.4 mg weekly | 15 mg weekly |
| Average weight loss | ~15–17% | ~20–22% |
| FDA approvals | Obesity, T2D, CVD, CKD, sleep apnea | Obesity, T2D, sleep apnea |
| Cost (list price) | ~$1,350/month | ~$1,060/month |
Tirzepatide's dual mechanism appears to produce greater average weight loss, though semaglutide's track record, broader approvals, and more mature long-term data make it a well-validated first-line choice for many patients.
Compounding Semaglutide: What to Know
During the semaglutide shortage that persisted from 2022 through 2025, FDA-registered compounding pharmacies were permitted to produce semaglutide under shortage exemptions. As of 2025, Wegovy and Ozempic have been removed from the FDA shortage list, which means compounding of copies of approved semaglutide formulations is no longer permitted under shortage exemptions.
Some pharmacies continue to compound semaglutide salts (e.g., semaglutide acetate or sodium), which differ from the approved formulations and remain in a legal gray zone as of early 2026. Always consult a licensed healthcare provider and verify that any compounding pharmacy is FDA-registered and PCAB-accredited.
Who Is a Candidate for Semaglutide?
Semaglutide (Wegovy) for weight management is FDA-approved for:
- Adults with a BMI ≥ 30 (obesity), or
- Adults with a BMI ≥ 27 (overweight) plus at least one weight-related comorbidity (type 2 diabetes, hypertension, high cholesterol, cardiovascular disease, or obstructive sleep apnea)
Semaglutide is contraindicated in:
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN2
- Pregnancy (or within 2 months of planned conception)
- Known hypersensitivity to semaglutide
Practical Considerations
Injection Technique
- Rotate injection sites each week to prevent lipodystrophy
- Inject into subcutaneous fat (not muscle) at the abdomen, thigh, or upper arm
- Store pens in the refrigerator; do not freeze. Pens in use can be kept at room temperature for up to 28 days
Managing Side Effects
- Start with smaller, lower-fat meals
- Eat slowly and stop before feeling full
- Avoid carbonated beverages during the first weeks of each dose increase
What Happens if You Stop?
Studies show that most patients regain a significant portion of lost weight within 12 months of stopping semaglutide. This is consistent with understanding obesity as a chronic condition — for sustained results, long-term treatment is typically required.
Conclusion
Semaglutide represents a genuine paradigm shift in obesity and metabolic medicine. With consistent double-digit weight loss in clinical trials, proven cardiovascular benefit, and an expanding list of FDA approvals, it has earned its place as a cornerstone therapy for millions of people managing obesity, type 2 diabetes, and related conditions.
No medication is without trade-offs, and semaglutide's gastrointestinal side effects, cost, and the reality of weight regain upon discontinuation are important considerations. But for appropriate candidates working with a qualified healthcare provider, semaglutide offers a degree of metabolic benefit that was unthinkable just a decade ago.
As higher doses enter trials and combination therapies emerge, the science of GLP-1 medicine is only accelerating. Semaglutide is where that revolution started.
This article is for informational and educational purposes only. It is not medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication.